SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
Westpac (ASX: WBC) Q1 Profit Rises 6% as Lending Growth and Treasury Income Strengthen Earnings 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
IRVINE, Calif., Jan. 03, 2018 -- TRIMEDYNE, INC. (OTCPINK “TMED”) today reported its financial results for its Fiscal Year ending on September 30, 2017.
For the Fiscal Year Ended September 30, 2017, Trimedyne had revenues of $4,695,000, a decrease of 8% from revenues of $5,109,000 for the prior year. We had a net loss for the current fiscal year of $44,000 or $0.36 per share, as compared to a net loss of $536,000 or $4.37 per share for the prior fiscal year, adjusted for a 150 to one reverse stock split in November, 2016. This 92% decrease in net loss as compared to the prior fiscal year is a considerable improvement, which was primarily the result of decreases in R&D expense and selling, general and administrative expense totaling $501,000, as we are continuing to carefully control our costs.
At the end of the fiscal year on September 30, 2017, we had cash and cash equivalents of $1,161,000, which included $580,000 in customer deposits for future orders, as compared to $307,000 at the end of the prior fiscal year.
Commenting on the financial results for the quarter, Marvin P. Loeb, Sc.D., Chairman of Trimedyne, said: “Since we are no longer required to file periodic reports with the SEC, our Financial Statements are un-audited. However, we believe our Financial Statements have been prepared and contain all adjustments of a recurring nature that are necessary for a fair appraisal of our operations and financial condition for the periods and dates shown below.
“We appreciate the patience of our shareholders and are working hard to improve our financial condition.”
CONTACT: Jeffrey Rudner (949) 951-3800, Ext. 285 [email protected]
